NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review

• Published in: Journal of the American College of Cardiology 2021-04, Vol.77 (16), p.2040-2052
• Main Authors: Oldham, William M, Hemnes, Anna R, Aldred, Micheala A, Barnard, John, Brittain, Evan L, Chan, Stephen Y, Cheng, Feixiong, Cho, Michael H, Desai, Ankit A, Garcia, Joe G N, Geraci, Mark W, Ghiassian, Susan D, Hall, Kathryn T, Horn, Evelyn M, Jain, Mohit, Kelly, Rachel S, Leopold, Jane A, Lindstrom, Sara, Modena, Brian D, Nichols, William C, Rhodes, Christopher J, Sun, Wei, Sweatt, Andrew J, Vanderpool, Rebecca R, Wilkins, Martin R, Wilmot, Beth, Zamanian, Roham T, Fessel, Joshua P, Aggarwal, Neil R, Loscalzo, Joseph, Xiao, Lei
• Format: Article
• Language: English
• Subjects: Biomedical Research - trends; Cardiovascular Diseases - classification; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - epidemiology; Computational Biology - methods; Computational Biology - trends; Education - trends; Humans; Lung Diseases - classification; Lung Diseases - diagnosis; Lung Diseases - epidemiology; National Heart, Lung, and Blood Institute (U.S.) - trends; Pulmonary Circulation - physiology; Research Report - trends; Review Literature as Topic; United States - epidemiology; Vascular Diseases - classification; Vascular Diseases - diagnosis; Vascular Diseases - epidemiology
• ISSN: 1558-3597; 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2021.02.056

The National Heart, Lung, and Blood Institute and the Cardiovascular Medical Research and Education Fund held a workshop on the application of pulmonary vascular disease omics data to the understanding, prevention, and treatment of pulmonary vascular disease. Experts in pulmonary vascular disease, omics, and data analytics met to identify knowledge gaps and formulate ideas for future research priorities in pulmonary vascular disease in line with National Heart, Lung, and Blood Institute Strategic Vision goals. The group identified opportunities to develop analytic approaches to multiomic datasets, to identify molecular pathways in pulmonary vascular disease pathobiology, and to link novel phenotypes to meaningful clinical outcomes. The committee suggested support for interdisciplinary research teams to develop and validate analytic methods, a national effort to coordinate biosamples and data, a consortium of preclinical investigators to expedite target evaluation and drug development, longitudinal assessment of molecular biomarkers in clinical trials, and a task force to develop a master clinical trials protocol for pulmonary vascular disease.